Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for future growth. Click for more on NTLA.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) on January 10 and set a price ...

RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, announced today that it has completed patient enrollment in its Phase 2 clinical trial for Purified ...

Shortly after arriving in Ottawa with her two young children, following her husband's appointment as Cameroon's High Commissioner (Ambassador) to Canada, Mercy Azoh-Mbi complained of fatigue, fever, a ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics ...

And yet, data science is now poised to usher in a level and acceleration of progress that even life sciences have never ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...